| Literature DB >> 34824196 |
Adriano Winterton1, Francesco Bettella1, Ann-Marie G de Lange1,2,3, Marit Haram1, Nils Eiel Steen1, Lars T Westlye1,2,3, Ole A Andreassen1,4, Daniel S Quintana5,6,7,8.
Abstract
Oxytocin is a neuromodulator and hormone that is typically associated with social cognition and behavior. In light of its purported effects on social cognition and behavior, research has investigated its potential as a treatment for psychiatric illnesses characterized by social dysfunction, such as schizophrenia and bipolar disorder. While the results of these trials have been mixed, more recent evidence suggests that the oxytocin system is also linked with cardiometabolic conditions for which individuals with severe mental disorders are at a higher risk for developing. To investigate whether the oxytocin system has a pleiotropic effect on the etiology of severe mental illness and cardiometabolic conditions, we explored oxytocin's role in the shared genetic liability of schizophrenia, bipolar disorder, type-2 diabetes, and several phenotypes linked with cardiovascular disease and type 2 diabetes risk using a polygenic pathway-specific approach. Analysis of a large sample with about 480,000 individuals (UK Biobank) revealed statistically significant associations across the range of phenotypes analyzed. By comparing these effects to those of polygenic scores calculated from 100 random gene sets, we also demonstrated the specificity of many of these significant results. Altogether, our results suggest that the shared effect of oxytocin-system dysfunction could help partially explain the co-occurrence of social and cardiometabolic dysfunction in severe mental illnesses.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34824196 PMCID: PMC8616952 DOI: 10.1038/s41398-021-01725-9
Source DB: PubMed Journal: Transl Psychiatry ISSN: 2158-3188 Impact factor: 6.222
Anthropometric and cardiovascular variables.
| Variable | Observation count | UK Biobank code(s) |
|---|---|---|
| BMI (kg/m2) | 485,323 | 21001 |
| BMI estimated by impedance (kg/m2) | 478,550 | 23104 |
| Waist-to-hip ratio | 486,124 | 48; 49 |
| Grip strength (kg) | 484,084 | 46; 47 |
| Whole-body fat percentage | 478,285 | 23099 |
| Trunk fat percentage | 478,235 | 23127 |
| Total daily energy intake (kJ) | 206,524 | 100002 |
| Total daily sugar intake (g) | 206,524 | 100008 |
| Total daily food weight (g) | 206,524 | 100001 |
| Loneliness | 478,140 | 2020 |
| Ability to confide | 469,417 | 2110 |
| Social contacts | 499,373 | 709; 1031 |
| Participation in social activities | 497,030 | 6160 |
Fig. 1Associations between continuous phenotypes.
Hierarchical analysis revealed three main clusters of associations: a BMI/body-fat cluster, a dietary cluster, and a grip strength/waist-to-hip ratio cluster. All variables within clusters were significantly associated with each other (all p’s < 0.05, FDR-corrected).
Fig. 2Distribution plots of the effect sizes of the PGSoxt and PC–PGSoxt models and models from PGSs calculated from 100 random gene sets of equal size for cluster principal components and individual variables.
A, B We found that a number of the statistically significant effects are specific to the oxytocin pathway and not due to the random association of the SNP in the gene set with the chosen phenotypes: schizophrenia, bipolar disorder, and type-2 diabetes mellitus. PGS polygenic score, PC1 first PGS principal component, PC2 second PGS principal component.
Fig. 3Effect sizes and confidence intervals for the linear models of the cluster principal components continuous phenotypes and logistic regression for the binary phenotypes.
A–C Different colors correspond to the three different PGSoxt’s and PC–PGSoxt’s. BD bipolar disorder, SCZ schizophrenia, T2D type-2 diabetes mellitus, PGSoxt polygenic score for the oxytocin pathway, PC1 first PGS principal component, PC2 second PGS principal component.